SUPATEEN: Children and Adolescents With Leukemia, Brain Tumors, and Sarcomas

Sponsor
Martin-Luther-Universität Halle-Wittenberg (Other)
Overall Status
Recruiting
CT.gov ID
NCT04101123
Collaborator
(none)
500
1
37.9
13.2

Study Details

Study Description

Brief Summary

Aim of this study is to investigate the influence of social factors on participation and activity among children and adolescents aged 10-18 years with leukemia, brain tumors, and sarcomas. Furthermore personal and treatment-related factors and their impact on participation will be explored

Condition or Disease Intervention/Treatment Phase
  • Other: Non-Interventional

Detailed Description

Background: About 2000 children and adolescents under the age of 18 develop cancer each year in Germany. Because of more differentiated diagnostics and standardized treatment protocols, a high survival rate can be reached for many types of the disease. Nevertheless, patients face a number of long-term effects related to the treatment. As a result, physical and psychological consequences have increasingly become the focus of research in recent years. Social dimensions of health have rarely been investigated in pediatric oncology so far. Yet, there are no robust results that allow an estimation of whether and to what extent the disease and treatment impair the participation of children and adolescents and which factors mediate this effect. Social participation is of great importance especially because interactions with peers and experiences in different areas of life are essential for the development of children and adolescents.

Methods: Data are collected in a longitudinal, prospective, observational multicenter study. For this purpose, all patients and their parents who are being treated for cancer in one of the participating clinics throughout Germany will be interviewed within the first month after diagnosis (t1), after completion of intensive treatment (t2) and half a year after the end of intensive treatment (t3) using standardized questionnaires. Analysis will be done by descriptive and multivariate methods.

Recruitment: Patients will be consecutively recruited in one of the participating clinics throughout Germany.

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Social Inequalities in the Participation and Activity in Children and Adolescents With Leukemia, Brain Tumors, and Sarcomas
Actual Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Feb 28, 2023

Arms and Interventions

Arm Intervention/Treatment
Children and adolescents with cancer

Children and adolescents between 10-18 years with newly diagnosed leukemia, brain tumors, and sarcomas

Other: Non-Interventional
Non-Interventional

Outcome Measures

Primary Outcome Measures

  1. Social participation and activity [Within the first month after diagnosis until half a year after intensive treatment]

    The Child and Adolescent Scale of Participation, CASP

  2. Level of quality of life [Within the first month after diagnosis until half a year after intensive treatment]

    Questionnaire to assess Health Related Quality of Life in chronically ill Children and Adolescents, KINDL Subscales: physical well-being, emotional well-being, self-esteem, family, friends, school, and a total score Values: range from 0 to 100 (higher values represent better quality of life)

Secondary Outcome Measures

  1. Evaluation of the treatment [End of intensive treatment]

    Questionnaire to assess the Satisfaction with the Treatment, FBB Subscales: success of treatment (range 0-20), relationship to medical team (range 0-28), treatment conditions (range 0-24), and a total score (range 0-72) Values: higher values represent better evaluation

  2. Self-concept [Within the first month after diagnosis until half a year after intensive treatment]

    Self-Description Questionnaire, SDQ

  3. Fatigue [Within the first month after diagnosis until half a year after intensive treatment]

    Subscale Fatigue from the Questionnaire to assess Quality of Life of Cancer Patients developed by the European Organisation for Research and Treatment of Cancer, EORTC QLQ-C30 Values: range from 0 to 100 (higher values represent higher symptoms of fatigue)

  4. Social support [Within the first month after diagnosis until half a year after intensive treatment]

    Social Support Scale, SSS Values: total score with a range 8-40 (higher values represent higher support)

  5. Illness perception [Within the first month after diagnosis until half a year after intensive treatment]

    Illness Perception Questionnaire, IPQ

  6. Self-efficacy [Within the first month after diagnosis until half a year after intensive treatment]

    General Self-Efficacy Scale; SWE

  7. Optimism [Within the first month after diagnosis until half a year after intensive treatment]

    Subscale from The Bern Subjective Well-Being Questionnaire for Adolescents, BFW

  8. Psychosocial problems and strengths [Within the first month after diagnosis until half a year after intensive treatment]

    Strengths and Difficulties Questionnaire, SDQ Subscales: emotional problems, conduct problems, peer problems, hyperactivity, and prosocial behavior Values: each scale has a range 0-10 (higher values represent higher problems except prosocial behavior)

  9. Sense of coherence [Within the first month after diagnosis until half a year after intensive treatment]

    Children Sense of Coherence Scale, C-SOC

  10. Coping [Within the first month after diagnosis until half a year after intensive treatment]

    Coping Questionnaire for Children and Adolescents, CODI

  11. Mental health [Within the first month after diagnosis until half a year after intensive treatment]

    Children's Depression Screener, Child-S

  12. Autonomy [Within the first month after diagnosis until half a year after intensive treatment]

    Subscale from The Kidscreen Questionnaire

Other Outcome Measures

  1. Parental coping with chronic childhood disease [Within the first month after diagnosis until half a year after intensive treatment]

    Coping Health Inventory for Parents, CHIP (parental questionnaire)

  2. Psychosocial needs [Within the first month after diagnosis until the end of intensive treatment]

    Short-Form Supportive Care Needs Survey Questionnaire, SCNS-SF34 (parental questionnaire)

  3. Evaluation of the treatment [End of intensive treatment]

    Questionnaire to assess the Satisfaction with the Treatment, FBB

  4. Familial burden [End of intensive treatment until half a year after intensive treatment]

    Impact on Family Scale in Families with Children with Disabilities, FaBel (parental questionnaire)

  5. Family resources [Within the first month after diagnosis and half a year after intensive treatment]

    Family Environment Scale, FES (parental questionnaire)

  6. Satisfaction with life [Within the first month after diagnosis until half a year after intensive treatment]

    The Satisfaction With Life Scale, SWL

  7. Doctor-parent relationship [End of intensive treatment]

    Patient Reactions Assessment, PRA-D

  8. Level of quality of life [Within the first month after diagnosis until half a year after intensive treatment]

    The Short Form Health Survey, SF-12

  9. Sense of coherence [Within the first month after diagnosis until half a year after intensive treatment]

    Sense of Coherence Scale - Leipziger Short Form, SOC-L9

  10. Mental health [Within the first month after diagnosis until half a year after intensive treatment]

    Hospital Anxiety and Depression Scale, HADS

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • newly diagnosed with confirmed leukemia, brain tumor or sarcoma

  • age 10-18 years

  • written informed consent of the patient and of one of the parents if they are under the age of 18

Exclusion Criteria:
  • having a relapse or secondary tumor

  • insufficient command of German

  • profound cognitive and physical impairments

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Medical Sociology Halle (Saale) Germany

Sponsors and Collaborators

  • Martin-Luther-Universität Halle-Wittenberg

Investigators

  • Study Chair: Matthias Richter, Prof. Dr., Martin-Luther-Universität Halle-Wittenberg

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Julia Roick, Research Associate, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier:
NCT04101123
Other Study ID Numbers:
  • 70113424
First Posted:
Sep 24, 2019
Last Update Posted:
Oct 6, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Julia Roick, Research Associate, Martin-Luther-Universität Halle-Wittenberg
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 6, 2021